Novo Nordisk, AMD and Alphabet
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...
Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its ...
Wegovy maker Novo Nordisk is not immune to tariffs U.S. President Donald Trump is threatening to levy on the European Union, ...
The company’s shares rose as investors breathed a sigh of relief on strong sales growth and guidance, despite ongoing ...
Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t ...
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...
Novo Nordisk's recent decline suggests it may be a Buy again, with strong growth prospects in diabetes and obesity treatments ...
Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...
LOS ANGELES, CA / ACCESS Newswire / February 5, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...
Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results